A break-away failure for oncology care models.

July 10, 2017. Will oncology be the next casualty of Brexit? This month’s ASCO op ed explores the cancer care fall-out of the UK’s departure from the EU. Drug approval processes are often fast-tracked via an EU regulatory body which will suffer a large void without the continued strong research presence of the UK. In fact, several clinical trials are conducted through single EU-registration processes. Same goes for pharmaceutical companies, who privately fund a significant portion of drug advances. For better or worse, Brexit brings big changes in clinical trial trajectories in Europe. One thing’s for sure: Like it’s English-speaking counterpart across the pond, the UK will have to work hard to keep cancer care a priority amidst an uncertain healthcare climate.

Comments

Popular Posts